A detailed history of Nuveen Asset Management, LLC transactions in Vera Therapeutics, Inc. stock. As of the latest transaction made, Nuveen Asset Management, LLC holds 159,024 shares of VERA stock, worth $7.36 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
159,024
Previous 141,847 12.11%
Holding current value
$7.36 Million
Previous $5.13 Million 36.93%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$34.09 - $46.71 $585,563 - $802,337
17,177 Added 12.11%
159,024 $7.03 Million
Q2 2024

Aug 09, 2024

SELL
$33.72 - $48.82 $167,790 - $242,928
-4,976 Reduced 3.39%
141,847 $5.13 Million
Q1 2024

May 13, 2024

SELL
$14.91 - $49.14 $765,792 - $2.52 Million
-51,361 Reduced 25.92%
146,823 $6.33 Million
Q4 2023

Feb 14, 2024

SELL
$9.29 - $16.0 $861,313 - $1.48 Million
-92,714 Reduced 31.87%
198,184 $3.05 Million
Q3 2023

Nov 14, 2023

BUY
$13.71 - $19.64 $1.69 Million - $2.42 Million
123,432 Added 73.71%
290,898 $3.99 Million
Q2 2023

Aug 14, 2023

BUY
$6.11 - $17.83 $540,899 - $1.58 Million
88,527 Added 112.15%
167,466 $2.69 Million
Q1 2023

May 15, 2023

SELL
$5.41 - $18.3 $103,855 - $351,305
-19,197 Reduced 19.56%
78,939 $612,000
Q4 2022

Feb 14, 2023

BUY
$15.74 - $22.19 $133,317 - $187,949
8,470 Added 9.45%
98,136 $1.9 Million
Q3 2022

Nov 14, 2022

BUY
$13.27 - $22.31 $203,614 - $342,324
15,344 Added 20.65%
89,666 $1.91 Million
Q2 2022

Aug 15, 2022

BUY
$12.82 - $23.4 $265,361 - $484,356
20,699 Added 38.6%
74,322 $1.01 Million
Q1 2022

May 16, 2022

BUY
$17.8 - $28.06 $685,745 - $1.08 Million
38,525 Added 255.17%
53,623 $1.14 Million
Q4 2021

Feb 14, 2022

BUY
$15.01 - $35.8 $226,620 - $540,508
15,098 New
15,098 $344,000

Others Institutions Holding VERA

About Vera Therapeutics, Inc.


  • Ticker VERA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 27,042,300
  • Market Cap $1.25B
  • Description
  • Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with ...
More about VERA
Track This Portfolio

Track Nuveen Asset Management, LLC Portfolio

Follow Nuveen Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nuveen Asset Management, LLC with notifications on news.